Flynn Sean, Jensen Rachel, Lane John, Bandyk Dennis, Malas Mahmoud, Barleben Andrew
Department of Surgery, University of California, San Diego, San Diego, CA.
Department of Surgery, University of California, San Diego, San Diego, CA; Department of Surgery, Veterans Administration Healthcare Services, San Diego, CA.
Ann Vasc Surg. 2020 Aug;67:300-305. doi: 10.1016/j.avsg.2020.02.010. Epub 2020 Mar 13.
Chronic iliocaval obstruction is a challenging clinical entity to treat. Endovenous iliocaval stenting is becoming the treatment of choice for central vein stenosis and occlusion. However, outcomes in thrombotic disease have not been as robust as nonthrombotic disease. In this article, we describe our experience utilizing covered stents as a novel tool for chronic total occlusions of the iliocaval veins.
We performed a retrospective review of a prospectively maintained database of all patients undergoing endovenous stenting with a covered stent for chronic occlusive iliocaval disease over a 3-year period at our institution. Patients were followed clinically and with venous duplexes to assess the feasibility, safety, and outcomes of iliocaval endovenous stenting with covered stents.
A total of 10 patients (8 men and 2 women) underwent iliocaval stenting with covered stents from July 2015 to May 2018. A total of 20 self-expanding covered stents (SECS) and 13 balloon expandable covered stents (BECS) were deployed in the central veins of the 10 patients. Six SECS and 5 BECS were deployed in the inferior vena cava, 10 SECS and 6 BECS were deployed in the common iliac veins (CIVs) (5 patients had bilateral CIV BECS and 2 patients had bilateral CIV SECS), and 4 SECS and 2 BECS were deployed in the external iliac veins (2 patients had bilateral SECS placed). Median follow-up time was 12.1 (range 0.5-35.0) months. There were no perioperative or postoperative complications. Nine (90%) patients maintained primary stent patency during our follow-up time. One patient (10%) had rethrombosis of his stent due to undertreated common femoral vein disease in the setting of a new myeloproliferative neoplasm and an inappropriate cessation of therapeutic anticoagulation. All patients who were symptomatic preoperatively had improvement in their pain, venous ulceration, and venous claudication. Eight of nine (89%) patients had improvement in their lower extremity edema.
Covered endovenous stenting of chronically occluded central veins is a safe and promising procedure. Their use may improve the short- and long-term outcomes in this challenging patient population. Further studies are required to evaluate the long-term efficacy and cost of their use.
慢性髂股静脉阻塞是一种具有挑战性的临床病症,治疗难度较大。腔内髂股静脉支架置入术正成为治疗中心静脉狭窄和闭塞的首选方法。然而,在血栓性疾病中的治疗效果不如非血栓性疾病显著。在本文中,我们描述了使用覆膜支架作为治疗慢性髂股静脉完全闭塞的新工具的经验。
我们对我院在3年期间接受腔内覆膜支架置入术治疗慢性闭塞性髂股静脉疾病的所有患者的前瞻性维护数据库进行了回顾性分析。对患者进行临床随访和静脉超声检查,以评估腔内髂股静脉覆膜支架置入术的可行性、安全性和疗效。
2015年7月至2018年5月,共有10例患者(8例男性,2例女性)接受了髂股静脉覆膜支架置入术。10例患者的中心静脉共置入了20枚自膨式覆膜支架(SECS)和13枚球囊扩张式覆膜支架(BECS)。6枚SECS和5枚BECS置入下腔静脉,10枚SECS和6枚BECS置入髂总静脉(5例患者双侧髂总静脉置入BECS,2例患者双侧髂总静脉置入SECS),4枚SECS和2枚BECS置入髂外静脉(2例患者双侧置入SECS)。中位随访时间为12.1(范围0.5 - 35.0)个月。无围手术期或术后并发症。9例(90%)患者在随访期间保持了支架的原发性通畅。1例患者(10%)因新发骨髓增殖性肿瘤时股总静脉疾病治疗不足以及不当停用治疗性抗凝药物导致支架再血栓形成。所有术前有症状的患者在疼痛、静脉溃疡和静脉性跛行方面均有改善。9例患者中有8例(89%)下肢水肿得到改善。
慢性闭塞性中心静脉的腔内覆膜支架置入术是一种安全且有前景的手术。其应用可能改善这一具有挑战性的患者群体的短期和长期治疗效果。需要进一步研究来评估其长期疗效和使用成本。